ContraFect Corporation (CFRX)
After hours:
| Previous close | 3.3400 |
| Open | 3.3500 |
| Bid | 3.0300 x 3100 |
| Ask | 3.4200 x 1000 |
| Day's range | 3.0200 - 3.4250 |
| 52-week range | 2.1100 - 4.7550 |
| Volume | |
| Avg. volume | 125,362 |
| Market cap | 120.751M |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8950 |
| Earnings date | 11 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.00 |
- GlobeNewswire
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections
YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing that the Company’s lead product candidate, exebacase, which has been designated as a Breakthrough Therapy for developm
- GlobeNewswire
ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022
YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected to present two posters at the ASM Microbe Conference to be held in Washington, D.C. from June 9-13, 2022. The
- GlobeNewswire
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinic
